{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:44:26Z","timestamp":1794444266576,"version":"4.9.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"Background:<\/jats:bold> Systemic cancer therapy has traditionally been administered using an intravenous (IV) route, implying patients\u2019 frequent visits to hospitals to access to their therapy. If we consider the actual pipeline in oncology, oral chemotherapy will be the main component of cancer treatment in the next few years. This shift in the administration route requires different care models in order to guarantee treatment efficacy and safety.<\/jats:p>Objective:<\/jats:bold> To analyze time trends in oral chemotherapy consumption in Portugal.<\/jats:p>Method:<\/jats:bold> Oral chemotherapy consumption over a 13-year period (2008\u20132020) was analyzed, considering dispensed units by the administration route with respective costs, resorting to the drug regulatory agency (INFARMED I.P.) database. Oral consumption patterns were further explored using common daily doses (CDD) for three conditions, including chronic myeloid leukemia (CML), non-small-cell lung cancer (NSCLC), and breast cancer (BC), to adjust for the effect of varying doses. Data were analyzed descriptively resorting to Microsoft Office Excel 2010.<\/jats:p>Results:<\/jats:bold> Overall chemotherapy consumption increased +\u039454.7%, with the highest contribution in units observed in oral forms (+\u039458.8%). The total expenditure increased +\u039496.5%, and despite the increase in oral forms (+\u0394221.6%), intravenous forms continued to be the major cost driver, with an important contribution from immunotherapy. Much of the increase was led by the approval of 40 new IV and 48 new oral cancer medications with higher costs introduced in the market. Using CDD as an alternative metric to units had varying impacts by indication. The observed increases seemed to focus on specific cancer sites with varying effect; in CML, there was a 2.39-fold increase, compared to 4.41 for NSCLC and 1.86 for BC. However, for BC, two distinct sub-patterns were observed for hormone therapy (increasing 1.83) and for the novel tyrosine kinase inhibitors (increasing 40.8).<\/jats:p>Conclusion:<\/jats:bold> The growing use of oral chemotherapy is obvious and calls for investments in supporting patients in managing medication adherence and adverse events. The shifts in the healthcare system are complex and need to be prioritized. Our data suggest that priority could be attributed to cancer sites driving innovation, namely, advanced breast cancer.<\/jats:p>","DOI":"10.3389\/fphar.2022.909948","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:00:07Z","timestamp":1660107607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["National trends in the use of oral chemotherapy over 13 years"],"prefix":"10.3389","volume":"13","author":[{"given":"A.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alves da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","unstructured":"Relat\u00f3rio de Atividade 20182019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CCO.0b013e328351fb29","article-title":"Clinical development of new formulations of cytotoxics in solid tumors","volume":"24","author":"Azim","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/pds.4282","article-title":"National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study","volume":"26","author":"Bosco-L\u00e9vy","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.breast.2022.02.005","article-title":"Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study","volume":"62","author":"Cardoso Borges","year":"2022","journal-title":"Breast"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1377\/hlthaff.2014.0001","article-title":"National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011","volume":"33","author":"Conti","year":"2014","journal-title":"Health Aff."},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10549-015-3383-6","article-title":"A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer","volume":"151","author":"Diaby","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B9","first-page":"231","article-title":"Adherence to targeted oral anticancer medications","volume":"15","author":"Geynisman","year":"2013","journal-title":"Discov. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/nejmoa1609324","article-title":"Long-term Outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B11","volume-title":"Consumption data of anticancer medications (pharmacotherapeutic code 16) 2008\u20132020. Provided by INFARMED upon authors\u2019 request","year":"2021"},{"key":"B12","unstructured":"Estimated age-standardized incidence and mortality rates (World) in 2020, worldwide, females, all ages2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1200\/JOP.2016.019729","article-title":"Treatment satisfaction and adherence to oral chemotherapy in patients with cancer","volume":"13","author":"Jacobs","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12094-012-0964-2","article-title":"An update on molecularly targeted therapies in secondand third-line treatment in non-small cell lung cancer: Focus on EGFR inhibitors and anti-angiogenic agents","volume":"15","author":"Majem","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.14694\/edbook_am.2015.35.e337","article-title":"Cancer care quality: Current state and future directions","author":"Shulman","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: Oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B18","volume-title":"Introduction to drug utilization research","year":"2003"},{"key":"B19","doi-asserted-by":"publisher","first-page":"71358","DOI":"10.18632\/oncotarget.20311","article-title":"The resistance mechanisms and treatment strategies for EGFRmutant advanced non-small-cell lung cancer","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.909948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:00:10Z","timestamp":1660107610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.909948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":19,"alternative-id":["10.3389\/fphar.2022.909948"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.909948","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"909948"}}